Antibody-guided diagnosis: an Italian experience on XXXX -expressing @entity5 .

@entity1 @entity0 @entity5 @entity2 @entity189 @entity787
Within the Italian CNR Biomedical Technology programmes a large multicentre clinical trial on @entity787 -expressing @entity189 has been carried out. F(ab')2 fragments of anti- @entity787 monoclonal antibody (MAb) FO23C5, radiolabelled with either 131I or 111In, were supplied to 10 different Italian nuclear medicine departments. Over 500 @entity1 with @entity0 have been investigated. The results obtained in our nuclear medicine department are reported here. In @entity5 group, the 131I compound showed better results except in liver metastases detected only in 28/57 @entity1 . In the @entity2 group, very satisfactory results were achieved in primary @entity5 and local or systemic recurrences: 111In tracer was preferentially used. In the @entity0 group immunoscintigraphy proved to be helpful in differential diagnosis of @entity5 . Significant improvements of diagnostic sensitivity were achieved in @entity5 @entity1 by means of i.p. administration. Finally, 12 @entity1 with advanced disease were given different 131I radioiodinated MAbs (100 mCi average dose). Administration route was either i.v. (3 cases) or i.p. (9 cases). Clinical and instrumental evidence of complete (1) or partial (7) response was observed in 8 @entity1 .
